Biotech | January 11, 2022
Takeda to acquire Adaptate Biotherapeutics
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
It has also been granted permission to conduct trials for booster dose
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Subscribe To Our Newsletter & Stay Updated
